U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07527975) titled 'Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102' on April 07.
Brief Summary: Long-Term Follow-up: Phase I/II clinical study to evaluate the safety and efficacy of the infusion of RP-L102
Study Start Date: Feb. 01, 2022
Study Type: OBSERVATIONAL
Condition:
Fanconi Anemia
Intervention:
BIOLOGICAL: RP-L102
CD34+ enriched cells from subjects with Fanconi anemia subtype A (FA-A) transduced ex vivo with lentiviral vector carrying the FANCA gene, PGK-FANCA-WPRE
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Rocket Pharmaceuticals Inc.
Published by HT Digital Con...